Cargando…

Differential Binding of Tenofovir and Adefovir to Reverse Transcriptase of Hepatitis B Virus

INTRODUCTION: Resistance of the reverse transcriptase (RT) of hepatitis B virus (HBV) to the tenofovir nucleotide drug has not been observed since its introduction for treatment of hepatitis B virus (HBV) infection in 2008. In contrast, frequent viral breakthrough and resistance has been documented...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Hemert, Formijn J., Berkhout, Ben, Zaaijer, Hans L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4152281/ https://www.ncbi.nlm.nih.gov/pubmed/25180507 http://dx.doi.org/10.1371/journal.pone.0106324

Ejemplares similares

Occult hepatitis B infection: an evolutionary scenario
por: van Hemert, Formijn J, et al.
Publicado: (2008)

Protein X of Hepatitis B Virus: Origin and Structure Similarity with the Central Domain of DNA Glycosylase
por: van Hemert, Formijn J., et al.
Publicado: (2011)

Nucleotide composition of the Zika virus RNA genome and its codon usage
por: van Hemert, Formijn, et al.
Publicado: (2016)

The Hepatitis B Virus X Protein Inhibits Thymine DNA Glycosylase Initiated Base Excision Repair
por: van de Klundert, Maarten A. A., et al.
Publicado: (2012)

Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study
por: Rodríguez, Manuel, et al.
Publicado: (2017)

On the biased nucleotide composition of the human coronavirus RNA genome
por: Berkhout, Ben, et al.
Publicado: (2015)

Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: A Systematic Review
por: Zhao, Shu-Shan, et al.
Publicado: (2011)

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
por: Park, Jung Gil, et al.
Publicado: (2015)

Silent codon positions in the A-rich HIV RNA genome that do not easily become A: Restrictions imposed by the RNA sequence and structure
por: Berkhout, Ben, et al.
Publicado: (2022)

Short-term efficacy after switching from adefovir dipivoxil and tenofovir disoproxil fumarate therapy to tenofovir alaferamide for chronic hepatitis B
por: Sano, Tomoya, et al.
Publicado: (2021)

Laboratory Evaluation of Three Regimens of Treatment of Chronic Hepatitis B: Tenofovir, Entecavir and Combination of Lamivudine and Adefovir
por: Jayakumar, Rajeswari, et al.
Publicado: (2012)

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
por: Woo, Hyun Young, et al.
Publicado: (2020)

Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant
por: Ratziu, Vlad, et al.
Publicado: (2006)

Different rates of (non-)synonymous mutations in astrovirus genes; correlation with gene function
por: van Hemert, Formijn J, et al.
Publicado: (2007)

Host-related nucleotide composition and codon usage as driving forces in the recent evolution of the Astroviridae
por: van Hemert, Formijn J., et al.
Publicado: (2007)

Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?
por: Song, Byung-Cheol
Publicado: (2016)

Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients
por: Chung, Goh Eun, et al.
Publicado: (2017)

Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)
por: Lee, Hye Won, et al.
Publicado: (2016)

Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations
por: Cassino, Lucila, et al.
Publicado: (2011)

The treatment of chronic hepatitis B: Focus on adefovir-like antivirals
por: Tillmann, Hans Ludger
Publicado: (2008)

Efficacy of tenofovir disoproxil fumarate switch therapy in chronic hepatitis B patients with suboptimal response to adefovir-based combination therapy
por: Li, Xiangyong, et al.
Publicado: (2019)

The A-nucleotide preference of HIV-1 in the context of its structured RNA genome
por: van Hemert, Formijn J., et al.
Publicado: (2013)

Low-dose adefovir dipivoxil–induced hypophosphatemia osteomalacia in five chronic hepatitis B virus–infected patients. Is low-dose adefovir dipivoxil–induced nephrotoxicity completely reversible?
por: Qian, Yan-Ying, et al.
Publicado: (2019)

Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients
por: Lee, Heon Ju, et al.
Publicado: (2018)

Effect of Hepatitis B Virus Genotypes on the Efficacy of Adefovir Dipivoxil Antiviral Therapy
por: Wen, Zhili, et al.
Publicado: (2014)

Euclidean Distance Analysis Enables Nucleotide Skew Analysis in Viral Genomes
por: van Hemert, Formijn, et al.
Publicado: (2018)

Comparing the efficacy and safety of tenofovir and adefovir or combined drug treatment for the treatment of chronic hepatitis B infection: a systematic review and meta-analysis
por: Bi, Zeyu, et al.
Publicado: (2022)

Lamivudine/Adefovir Treatment Increases the Rate of Spontaneous Mutation of Hepatitis B Virus in Patients
por: Pereira-Gómez, Marianoel, et al.
Publicado: (2016)

The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
por: Kim, Jeong Han, et al.
Publicado: (2016)

Structure of the HIV-1 reverse transcriptase Q151M mutant: insights into the inhibitor resistance of HIV-1 reverse transcriptase and the structure of the nucleotide-binding pocket of Hepatitis B virus polymerase
por: Nakamura, Akiyoshi, et al.
Publicado: (2015)

Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma
por: Yang, Xunjun, et al.
Publicado: (2016)

Pharmacokinetics and Pharmacodynamics of the Reverse Transcriptase Inhibitor Tenofovir and Prophylactic Efficacy against HIV-1 Infection
por: Duwal, Sulav, et al.
Publicado: (2012)

Comparison of the Efficacies and Safety of Combined Therapy between Telbivudine Plus Adefovir and Lamivudine Plus Adefovir in Patients with Hepatitis B Virus Infection in Real-World Practice
por: Lin, Ming-Tsung, et al.
Publicado: (2016)

A comparison of treatment with adefovir and entecavir for chronic hepatitis B in China: The 2-year results of a prospective study: Adefovir versus Entercavir for Chronic Hepatitis B
por: Chen, En Qiang, et al.
Publicado: (2011)

HIV-1 tolerates changes in A-count in a small segment of the pol gene
por: Klaver, Bep, et al.
Publicado: (2017)

Meta-analysis: Adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus
por: Chen, En-Qiang, et al.
Publicado: (2009)

Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus
por: Woo, Hyun Young, et al.
Publicado: (2014)

Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections
por: Lin, Ming-Tsung, et al.
Publicado: (2013)

Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy
por: WANG, YANG, et al.
Publicado: (2016)

Hepatitis B Virus–Telomerase Reverse Transcriptase Promoter Integration Harnesses Host ELF4, Resulting in Telomerase Reverse Transcriptase Gene Transcription in Hepatocellular Carcinoma
por: Sze, Karen Man‐Fong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8jnnouv1aipkqn7dtiqs0dh0qm